FBLN7

Across TCGA pan-cancer cohorts, FBLN7 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of FBLN7’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where FBLN7 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FBLN7 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRC, THCA, and KIRP are the cancer types where FBLN7 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBLN7 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+2.080	<.001	12	view →
THCA	All	IV	−2.100	<.001	11	view →
KIRP	Male	II,III,IV	+1.624	<.001	9	view →
LIHC	Male	All	+1.039	<.001	8	view →
BRCA	Female	II,III,IV	−0.629	<.001	6	view →
COAD	Female	III,IV	−0.502	.003	5	view →
HNSC	All	All	+0.410	.008	5	view →
BLCA	All	All	−0.607	.014	4	view →
PAAD	Male	All	+1.004	.047	2	view →
LUAD	All	All	+0.254	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

FBLN7–KIRC

Open the KIRC breakdown →